Abstract
During the emerging second wave of COVID-19 in India in the previous two months, of rare fungal infections the Mucormycosis, was reported and alarmed the possible epidemic of this fungal disease in COVID-19 patients and recovered persons(2). The total number of reported Mucormycosis infections is high in India as compared to the global reports(8). The limited oxygen supplies and the rising of the country's death toll during COVID-19 with the highest record of daily new cases attributed to many reasons including the new variant B.1.617 (delta variant) reported in India and 78 other countries(10,11).